FDA Rejection, Evox-Rett Partnership, AI in Healthcare, Rezatapopt Study, Alzheimer's LLM Framework

In today's episode, we delve into the unexpected FDA rejection of a rare disease drug initially deemed approvable, highlighting the complexities of the drug approval process. We also explore Evox Therapeutics' partnership with the Rett Syndrome Research Trust to develop gene editing therapies using their ExoEdit® platform. NEJM AI emphasizes the need for rigorous trials and ethical considerations in healthcare AI development. The ViVE 2026 conference shifts focus from AI scribes to strategic applications, amid regulatory discussions on AI's role in insurance. Researchers initiate a Phase 1 study of Rezatapopt for TP53 Y220C mutation-related cancers, showing promising early results. Finally, a novel framework using large language models enhances Alzheimer's drug prioritization, offering a scalable approach to accelerate drug repurposing.

https://www.lucidhealthsolutions.com

https://www.lucidhealthsolutions.com

📚 Sources:

• https://www.statnews.com/2026/02/25/sarepta-ceo-doug-ingram-to-retire/
• https://www.biospace.com/press-releases/evox-therapeutics-partners-with-rett-syndrome-research-trust-to-evaluate-exoedit-technology-to-enable-gene-editing-in-rett-syndrome
• https://ai.nejm.org/
• https://www.modernhealthcare.com/health-tech/mh-vive-2026-ai-agents-ambient-scribes/
• https://www.nejm.org/doi/full/10.1056/NEJMoa2508820
• https://www.nature.com/articles/s44401-026-00074-3

What is NextGen Patient Voice?

NextGen Patient Voice explores how research, AI, and public policy are transforming patient advocacy. Each episode breaks down the ideas, tools, and decisions shaping the future of healthcare, with a focus on what they mean for patients, caregivers, and advocates. Clear, practical, and forward-looking, this podcast connects innovation to real-world patient impact.